Business Context and Reporting Period
Company: Myriad Genetics, Inc. (MYGN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Myriad is a leading molecular diagnostics and precision medicine company. Its portfolio focuses on three core areas: Oncology (hereditary cancer and tumor profiling), Women's Health (prenatal screening), and Mental Health (pharmacogenomics). The company operates as a single operating segment.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $824.5 million | $837.6 million | (2)% |
| Gross Profit | $576.6 million | $585.4 million | (1.5)% |
| Gross Margin | 69.9% | 69.9% | 0% |
| Net Loss | $(365.9) million | $(127.3) million | Worsened |
| Loss Per Share (Diluted) | $(3.95) | $(1.41) | Worsened |
| Operating Cash Flow | $1.8 million | $(8.7) million | $10.5 million improvement |
| Cash and Equivalents | $149.6 million | $102.4 million | $47.2 million increase |
| Long-Term Debt (Net) | $119.9 million | $39.6 million | $80.3 million increase |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2% year-over-year. While total testing volumes increased 1%, revenue was negatively impacted by a 15% decline in Mental Health revenue (driven by UnitedHealthcare coverage changes for GeneSight) and a 3% decline in Tumor Profiling revenue (due to the prior year divestiture of EndoPredict).
- Significant Impairment Charges: The company recorded $319.4 million in goodwill and long-lived asset impairment charges in 2025, compared to $56.8 million in 2024. This was triggered by a sustained decline in market capitalization and downward forecast revisions, primarily affecting the Women's Health and Mental Health reporting units.
- Debt Restructuring: In July 2025, the company entered a new $200 million term loan facility with OrbiMed, funding an initial $125 million loan. Proceeds were used to repay the previous asset-based revolving credit facility in full.
- Management Transition: Significant leadership changes occurred in 2025, including the appointment of Samraat S. Raha as CEO and Benjamin R. Wheeler as CFO.
Guidance, Outlook, and Risks
- Strategic Focus: Management is prioritizing the Cancer Care Continuum (CCC), specifically Molecular Residual Disease (MRD) testing, while aiming to grow Prenatal and Mental Health revenues at or above market rates.
- Key Risks:
- Reimbursement Pressure: Continued negative impact from UnitedHealthcare's decision to stop covering certain multi-gene panel pharmacogenetic tests (GeneSight) is expected to persist into 2026.
- Debt Covenants: The new Credit Facility includes a minimum trailing twelve-month revenue covenant starting at $615 million in Q4 2025, increasing to $974 million by Q4 2029. Failure to meet these could trigger a default.
- Regulatory Uncertainty: Ongoing uncertainty regarding FDA regulation of Laboratory Developed Tests (LDTs) and potential changes in healthcare policy.
- Liquidity: Management believes existing cash ($149.6 million) and available borrowing capacity ($75 million undrawn) are sufficient for at least the next 12 months.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to meet the escalating minimum revenue covenants ($615M to $974M) under the new OrbiMed Credit Facility.
- GeneSight Reimbursement: Monitor the trajectory of Mental Health revenue and any updates on payor coverage policies following the UnitedHealthcare decision.
- Impairment Sustainability: Assess whether the $319.4 million impairment charge was a one-time event or if further write-downs are likely given the current market capitalization and stock price volatility.
- Product Pipeline Execution: Track the commercial launch and adoption rates of new products like FirstGene (prenatal) and Precise MRD (oncology) to offset revenue declines in legacy segments.
- Cash Burn vs. Generation: Confirm that operating cash flow remains positive despite the net loss, ensuring the company does not need to raise additional equity or debt sooner than anticipated.